Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
Authors:
- 13 January 2022
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1877 (1) , 188677
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated ActivationAngewandte Chemie International Edition, 2012
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activityProceedings of the National Academy of Sciences, 2012
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted TherapyMolecular Cancer Therapeutics, 2011
- RNA interference in the clinic: challenges and future directionsNature Reviews Cancer, 2010
- Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Nature Reviews Cancer, 2010
- Ras historySmall GTPases, 2010
- GEFs and GAPs: Critical Elements in the Control of Small G ProteinsCell, 2007
- Review of the Application of RNA Interference Technology in the Pharmaceutical IndustryToxicologic Pathology, 2007
- An Unidentified Virus which causes the Rapid Production of Tumours in MiceNature, 1964